The fact
The neurotechnology startup faces questions about feasibility of its ambitious goals and development pathway.
Critics challenge the realism of promises against current biological and regulatory hurdles.
17 sources — click a link to read an article on the topic:
Story timeline
Apr 14Did Neuralink make the wrong bet on neural chip technology?this article